{"entity":{"id":"nct05632809","kind":"trial","name":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)","aka":[],"tldr":"A phase 2 trial of durvalumab in lung cancer, run by M.D. Anderson Cancer Center, now recruiting.","summary":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) is a phase 2, interventional study registered as NCT05632809 by M.D. Anderson Cancer Center, with a registry enrolment figure of 39 participants, started 2023-01-10 and due to reach its primary completion in 2027-12-31. Interventions recorded: NKTR-255; Durvalumab. Conditions listed: Lung Cancer. Primary outcome: Overall survival time distribution. Lung eligibility wording from the registry: \"Histologic diagnosis of non-small cell lung cancer\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT05632809","url":"https://clinicaltrials.gov/study/NCT05632809"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["lung-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":["durvalumab"],"companies":["nektar-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05632809","phase":"2","setting":"REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)","sponsor":"M.D. Anderson Cancer Center","enrolled":39,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05632809/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"imrt-igrt","kind":"technology","name":"IMRT / IGRT (modern external beam)","route":"/technologies/imrt-igrt/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"}],"company":[{"id":"nektar-therapeutics","kind":"company","name":"Nektar Therapeutics","route":"/companies/nektar-therapeutics/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}